Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells

Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, the...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 17; p. 4266
Main Authors Kung, Fang-Ping, Lim, Yun-Ping, Chao, Wen-Ying, Zhang, Yi-Sheng, Yu, Hui-I, Tai, Tsai-Sung, Lu, Chieh-Hsiang, Chen, Shu-Hsin, Li, Yi-Zhen, Zhao, Pei-Wen, Yen, Yu-Pei, Lee, Ying-Ray
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 24.08.2021
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL.
AbstractList Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL.Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL.
Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL.
Simple SummaryThere is no effective treatment currently available for patients with anaplastic, recurrent papillary, or follicular thyroid cancers. Reactive oxygen species (ROS) are believed to hold promise as a new therapeutic strategy for multiple human cancers. However, studies on ROS inducers for human thyroid cancer treatment are scarce. This study assesses the anticancer activity and the detailed downstream mechanisms of piperlongumine, a ROS inducer, in human thyroid cancer cells. We demonstrate that piperlongumine inhibits cell proliferation, regulates the cell cycle, and induces cellular apoptosis in various types of human thyroid cancer cells. The antihuman thyroid cancer activity of piperlongumine was through ROS induction, and it further suppressed the downstream Akt signaling pathway to elevate mitochondria-dependent apoptosis. A mouse xenograft study demonstrated that piperlongumine was safe and could inhibit tumorigenesis in vivo. The present study provides strong evidence that piperlongumine can be used as a therapeutic candidate for human thyroid cancers.AbstractThyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into well-differentiated, poorly differentiated, and undifferentiated types, depending on the histological and clinical parameters. Thus far, there are no effective treatments for undifferentiated thyroid cancers or advanced and recurrent cancer. Therefore, the development of an effective therapeutic is urgently needed for such patients. Piperlongumine (PL) is a naturally occurring small molecule derived from long pepper; it is selectively toxic to cancer cells by generating reactive oxygen species (ROS). In this study, we demonstrate the potential anticancer activity of PL in four TC cell lines. For this purpose, we cultured TC cell lines and analyzed the following parameters: Cell viability, colony formation, cell cycle, apoptosis, and cellular ROS induction. PL modulated the cell cycle, induced apoptosis, and suppressed tumorigenesis in TC cell lines in a dose- and time-dependent manner through ROS induction. Meanwhile, an intrinsic caspase-dependent apoptosis pathway was observed in the TC cells under PL treatment. The activation of Erk and the suppression of the Akt/mTOR pathways through ROS induction were seen in cells treated with PL. PL-mediated apoptosis in TC cells was through the ROS-Akt pathway. Finally, the anticancer effect and safety of PL were also demonstrated in vivo. Our findings indicate that PL exhibits antitumor activity and has the potential for use as a chemotherapeutic agent against TC. This is the first study to show the sensitivity of TC cell lines to PL.
Author Zhang, Yi-Sheng
Chen, Shu-Hsin
Kung, Fang-Ping
Lim, Yun-Ping
Yu, Hui-I
Lee, Ying-Ray
Tai, Tsai-Sung
Li, Yi-Zhen
Zhao, Pei-Wen
Chao, Wen-Ying
Yen, Yu-Pei
Lu, Chieh-Hsiang
AuthorAffiliation 7 Department of Microbiology and Immunology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
5 Department of Nursing, Min-Hwei College of Health Care Management, Tainan 73658, Taiwan; A129@o365.mhchcm.edu.tw
3 Department of Internal Medicine, China Medical University Hospital, Taichung 404332, Taiwan
1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; 07266@cych.org.tw (F.-P.K.); 04490@cych.org.tw (H.-I.Y.); 04015@cych.org.tw (T.-S.T.); 02602@cych.org.tw (C.-H.L.); 15159@cych.org.tw (Y.-P.Y.)
4 Department of Medical Research, China Medical University Hospital, Taichung 404332, Taiwan
6 Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; s1030722@alumni.ncyu.edu.tw (Y.-S.Z.); 10472@cych.org.tw (S.-H.C.); 10862@cych.org.tw (Y.-Z.L.); 14421@cych.org.tw (P.-W.Z.)
2 Department of Pharmacy,
AuthorAffiliation_xml – name: 3 Department of Internal Medicine, China Medical University Hospital, Taichung 404332, Taiwan
– name: 7 Department of Microbiology and Immunology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
– name: 2 Department of Pharmacy, College of Pharmacy, China Medical University, Taichung 406040, Taiwan; limyp@mail.cmu.edu.tw
– name: 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; 07266@cych.org.tw (F.-P.K.); 04490@cych.org.tw (H.-I.Y.); 04015@cych.org.tw (T.-S.T.); 02602@cych.org.tw (C.-H.L.); 15159@cych.org.tw (Y.-P.Y.)
– name: 6 Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 60002, Taiwan; s1030722@alumni.ncyu.edu.tw (Y.-S.Z.); 10472@cych.org.tw (S.-H.C.); 10862@cych.org.tw (Y.-Z.L.); 14421@cych.org.tw (P.-W.Z.)
– name: 4 Department of Medical Research, China Medical University Hospital, Taichung 404332, Taiwan
– name: 5 Department of Nursing, Min-Hwei College of Health Care Management, Tainan 73658, Taiwan; A129@o365.mhchcm.edu.tw
Author_xml – sequence: 1
  givenname: Fang-Ping
  surname: Kung
  fullname: Kung, Fang-Ping
– sequence: 2
  givenname: Yun-Ping
  surname: Lim
  fullname: Lim, Yun-Ping
– sequence: 3
  givenname: Wen-Ying
  surname: Chao
  fullname: Chao, Wen-Ying
– sequence: 4
  givenname: Yi-Sheng
  surname: Zhang
  fullname: Zhang, Yi-Sheng
– sequence: 5
  givenname: Hui-I
  surname: Yu
  fullname: Yu, Hui-I
– sequence: 6
  givenname: Tsai-Sung
  surname: Tai
  fullname: Tai, Tsai-Sung
– sequence: 7
  givenname: Chieh-Hsiang
  surname: Lu
  fullname: Lu, Chieh-Hsiang
– sequence: 8
  givenname: Shu-Hsin
  surname: Chen
  fullname: Chen, Shu-Hsin
– sequence: 9
  givenname: Yi-Zhen
  surname: Li
  fullname: Li, Yi-Zhen
– sequence: 10
  givenname: Pei-Wen
  surname: Zhao
  fullname: Zhao, Pei-Wen
– sequence: 11
  givenname: Yu-Pei
  surname: Yen
  fullname: Yen, Yu-Pei
– sequence: 12
  givenname: Ying-Ray
  surname: Lee
  fullname: Lee, Ying-Ray
BookMark eNp1ksFu1DAQhi1UREvpmaslLhy6rGM78fqCFEVAK1XqCgpXy-vMblwSO9hOUd6Jh8TbLRKshC_jGX8z4380L9GJ8w4Qel2Qd4xJsjTaGQixYIXgtKqeoTNKBF1UleQnf91P0UWM9yQflslKvECnjJeEEcHP0K-1HSH03u2mwTq4xBqvfQKXcO2SPXTA625OPnUQ9AhTjl7ia9dOBiJuoO9xM5secB0CxIS1a3E9-jH5aGPm8Debgn8MPzoPHqcu-GnXZQv48-2XZf094bVO3U89Y-vw1TRoh--6OXjb4ubwhX2j-Ao93-o-wsWTPUdfP364a64WN7efrpv6ZmGYXKUFbKRk1Qa0zoIBSkOL1khuSkFLrmlbbkpi9FYC4boiZiu4YFAQIlaECcqBnaP3h7rjtBmgNXkcQfdqDHbQYVZeW_Xvi7Od2vkHteJ0RRnNBd4-FQj-x5THogYbTZagHfgpKlqKQlJCuMzomyP03k_BZXl7ilS0kIXIVHmgTPAxBtgqY5NO1u_7214VRO1XQh2tRM5bHuX9EfG_jN8JQ71X
CitedBy_id crossref_primary_10_1002_slct_202402022
crossref_primary_10_1016_j_diagmicrobio_2024_116578
crossref_primary_10_1007_s12032_023_02282_5
crossref_primary_10_3390_bioengineering12010007
crossref_primary_10_3389_fphar_2023_1223153
crossref_primary_10_3390_antiox14010094
crossref_primary_10_3390_pharmaceutics15030801
crossref_primary_10_62347_MINX1330
crossref_primary_10_1016_j_ijpharm_2023_123212
crossref_primary_10_1038_s41598_024_55870_4
crossref_primary_10_3390_cancers15041335
crossref_primary_10_3389_fonc_2022_861206
crossref_primary_10_1016_j_phymed_2022_154528
crossref_primary_10_1016_j_jddst_2024_106556
crossref_primary_10_3390_ijms24098048
crossref_primary_10_1016_j_heliyon_2024_e32390
crossref_primary_10_1080_15287394_2024_2308801
crossref_primary_10_1007_s42535_023_00598_1
crossref_primary_10_62347_DNTG2917
crossref_primary_10_1016_j_biopha_2022_113760
crossref_primary_10_1016_j_biopha_2023_114554
crossref_primary_10_3390_ijms25105395
crossref_primary_10_1016_j_trsl_2024_04_004
crossref_primary_10_1080_11263504_2024_2421229
crossref_primary_10_1002_ardp_202300768
crossref_primary_10_1177_09731296241300874
crossref_primary_10_2174_0118715303295608240408082523
Cites_doi 10.1016/j.phrs.2020.104772
10.1002/jat.1311
10.1245/ASO.2004.03.066
10.18632/oncotarget.3444
10.7314/APJCP.2014.15.7.3211
10.1016/j.freeradbiomed.2009.12.022
10.1158/1078-0432.CCR-12-1424
10.1002/jat.1261
10.1016/S0040-4020(01)82575-8
10.1016/j.tcb.2018.02.003
10.1039/C3NR06599E
10.1007/s10495-019-01553-9
10.3390/ijms21124218
10.1038/aps.2014.141
10.1155/2015/294303
10.1080/15384047.2015.1026511
10.1038/srep26357
10.3390/ijms17040616
10.1016/j.phrs.2016.11.038
10.7150/ijbs.35265
10.1158/1055-9965.EPI-13-1150
10.1093/bmb/ldr030
10.1097/00005537-200403000-00001
10.1186/s12943-017-0648-1
10.1016/j.leukres.2012.11.009
10.1007/s10495-017-1422-y
10.1111/jcmm.13474
10.1124/mol.117.111450
10.1016/j.ejps.2012.12.003
10.3390/ijms16036153
10.14348/molcells.2015.2235
10.3390/ijms19010312
10.1007/s13277-016-4792-9
10.1002/cncr.20936
10.1177/0394632015598849
10.1590/S0100-879X2006000600014
10.1016/j.ecl.2018.10.010
10.1016/j.bbrc.2017.10.061
10.1016/j.cbi.2019.01.003
10.1016/j.biopha.2018.10.182
10.1002/bio.3414
10.1016/j.bbrc.2013.06.042
10.3892/ijo.2014.2566
10.1111/nyas.13980
10.1155/2011/792639
10.18632/oncotarget.2402
10.1016/j.biopha.2012.08.001
10.3892/ol.2015.3371
10.1016/j.ejmech.2018.06.057
10.1007/s11095-012-0727-3
10.1080/01635581.2018.1445769
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOI 10.3390/cancers13174266
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Biological Science Collection
Research Library
Biological science database
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC8428232
10_3390_cancers13174266
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
TUS
3V.
7T5
7TO
7XB
8FK
H94
MBDVC
PKEHL
PQEST
PQGLB
PQUKI
Q9U
7X8
5PM
ID FETCH-LOGICAL-c398t-eb9936beaa331ee5c21dc94c57254a2d5b50caf9e04a60cf7473e1007803724e3
IEDL.DBID M48
ISSN 2072-6694
IngestDate Thu Aug 21 17:50:41 EDT 2025
Fri Jul 11 03:59:05 EDT 2025
Fri Jul 25 11:55:36 EDT 2025
Tue Jul 01 01:28:01 EDT 2025
Thu Apr 24 23:10:17 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 17
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c398t-eb9936beaa331ee5c21dc94c57254a2d5b50caf9e04a60cf7473e1007803724e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers13174266
PMID 34503074
PQID 2570621917
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8428232
proquest_miscellaneous_2571920049
proquest_journals_2570621917
crossref_citationtrail_10_3390_cancers13174266
crossref_primary_10_3390_cancers13174266
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210824
PublicationDateYYYYMMDD 2021-08-24
PublicationDate_xml – month: 8
  year: 2021
  text: 20210824
  day: 24
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Cancers
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Liu (ref_46) 2015; 2015
ref_50
Zheng (ref_13) 2016; 6
Hua (ref_4) 2012; 29
Chintakuntlawar (ref_48) 2019; 48
Duan (ref_19) 2016; 37
Li (ref_24) 2015; 10
ref_11
Xiao (ref_36) 2014; 23
Yao (ref_41) 2014; 15
Bezerra (ref_26) 2008; 28
ref_52
Mohammad (ref_18) 2019; 24
Kebebew (ref_3) 2005; 103
Chatterjee (ref_6) 1967; 23
Piska (ref_40) 2019; 300
Solis (ref_47) 2009; 1795
Oblad (ref_22) 2018; 94
Hodgson (ref_1) 2004; 11
Circu (ref_43) 2010; 48
Roh (ref_12) 2014; 5
Liu (ref_21) 2017; 494
Zhao (ref_29) 2017; 16
Fallahi (ref_34) 2015; 16
Han (ref_8) 2013; 37
Bezerra (ref_25) 2006; 39
Thongsom (ref_16) 2017; 22
Lee (ref_14) 2015; 38
Song (ref_9) 2018; 70
Lu (ref_49) 2012; 66
Chen (ref_15) 2015; 6
Stassi (ref_31) 2003; 63
Liu (ref_33) 2018; 33
Son (ref_28) 2011; 2011
Shaha (ref_5) 2004; 114
Bezerra (ref_7) 2013; 48
Cao (ref_42) 2019; 15
Mohler (ref_27) 2014; 45
Bezerra (ref_32) 2008; 28
Tripathi (ref_23) 2020; 156
Wang (ref_37) 2015; 28
Nogueira (ref_44) 2013; 19
McArthur (ref_30) 2018; 28
Piska (ref_38) 2018; 156
Lu (ref_51) 2017; 115
Pistollato (ref_35) 2019; 1443
Liu (ref_39) 2014; 6
Huang (ref_53) 2018; 22
Liu (ref_10) 2013; 437
Xiong (ref_45) 2015; 36
Vanderpump (ref_2) 2011; 99
Kumar (ref_20) 2019; 109
Golovine (ref_17) 2015; 16
References_xml – volume: 156
  start-page: 104772
  year: 2020
  ident: ref_23
  article-title: Piperlongumine, a Potent Anticancer Phytotherapeutic: Perspectives on Contemporary Status and Future Possibilities as an Anticancer Agent
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2020.104772
– volume: 28
  start-page: 599
  year: 2008
  ident: ref_32
  article-title: In Vivo Growth Inhibition of Sarcoma 180 by Piperlonguminine, an Alkaloid Amide from the Piper Species
  publication-title: J. Appl. Toxicol.
  doi: 10.1002/jat.1311
– volume: 11
  start-page: 1093
  year: 2004
  ident: ref_1
  article-title: Thyroid Cancer: Is the Incidence Still Increasing?
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/ASO.2004.03.066
– volume: 6
  start-page: 6406
  year: 2015
  ident: ref_15
  article-title: Piperlongumine Selectively Kills Hepatocellular Carcinoma Cells and Preferentially Inhibits their Invasion via ROS-ER-MAPKs-CHOP
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3444
– volume: 15
  start-page: 3211
  year: 2014
  ident: ref_41
  article-title: Radio-sensitization by Piper Longumine of Human Breast Adenoma MDA-MB-231 Cells In Vitro
  publication-title: Asian Pac. J. Cancer Prev.
  doi: 10.7314/APJCP.2014.15.7.3211
– volume: 48
  start-page: 749
  year: 2010
  ident: ref_43
  article-title: Reactive Oxygen Species, Cellular Redox Systems, and Apoptosis
  publication-title: Free Radic. Biol. Med.
  doi: 10.1016/j.freeradbiomed.2009.12.022
– volume: 19
  start-page: 4309
  year: 2013
  ident: ref_44
  article-title: Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-1424
– volume: 28
  start-page: 156
  year: 2008
  ident: ref_26
  article-title: In Vitro and In Vivo Antitumor Effect of 5-FU Combined with Piplartine and Piperine
  publication-title: J. Appl Toxicol.
  doi: 10.1002/jat.1261
– volume: 23
  start-page: 1769
  year: 1967
  ident: ref_6
  article-title: Alkaloids of Piper longum Linn. I. Structure and Synthesis of Piperlongumine and Piperlonguminine
  publication-title: Tetrahedron
  doi: 10.1016/S0040-4020(01)82575-8
– volume: 28
  start-page: 475
  year: 2018
  ident: ref_30
  article-title: Apoptotic Caspases: Multiple or Mistaken Identities?
  publication-title: Trends Cell Biol.
  doi: 10.1016/j.tcb.2018.02.003
– volume: 6
  start-page: 4325
  year: 2014
  ident: ref_39
  article-title: Biodegradable Nanoassemblies of Piperlongumine Display Enhanced Anti-angiogenesis and Anti-tumor Activities
  publication-title: Nanoscale
  doi: 10.1039/C3NR06599E
– volume: 24
  start-page: 730
  year: 2019
  ident: ref_18
  article-title: JNK Inhibition Blocks Piperlongumine-Induced Cell Death and Transcriptional Activation of Heme Oxygenase-1 in Pancreatic Cancer Cells
  publication-title: Apoptosis
  doi: 10.1007/s10495-019-01553-9
– ident: ref_52
  doi: 10.3390/ijms21124218
– volume: 36
  start-page: 362
  year: 2015
  ident: ref_45
  article-title: Piperlongumine Induces Apoptotic and Autophagic Death of the Primary Myeloid Leukemia Cells from Patients via Activation of ROS-p38/JNK Pathways
  publication-title: Acta. Pharmacol. Sin.
  doi: 10.1038/aps.2014.141
– volume: 2015
  start-page: 294303
  year: 2015
  ident: ref_46
  article-title: Increased Oxidative Stress as a Selective Anticancer Therapy
  publication-title: Oxid. Med. Cell Longev.
  doi: 10.1155/2015/294303
– volume: 16
  start-page: 743
  year: 2015
  ident: ref_17
  article-title: Piperlongumine and its Analogs Down-regulate Expression of c-Met in Renal Cell Carcinoma
  publication-title: Cancer Biol. Ther.
  doi: 10.1080/15384047.2015.1026511
– volume: 6
  start-page: 26357
  year: 2016
  ident: ref_13
  article-title: Piperlongumine Inhibits Lung Tumor Growth via Inhibition of Nuclear Factor Kappa B signaling Pathway
  publication-title: Sci. Rep.
  doi: 10.1038/srep26357
– ident: ref_11
  doi: 10.3390/ijms17040616
– volume: 115
  start-page: 288
  year: 2017
  ident: ref_51
  article-title: Honokiol, a Potential Therapeutic Agent, Induces Cell Cycle Arrest and Program Cell Death In Vitro and In Vivo in Human Thyroid Cancer Cells
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2016.11.038
– volume: 15
  start-page: 1676
  year: 2019
  ident: ref_42
  article-title: Enhancement of Oxaliplatin-induced Colon Cancer Cell Apoptosis by Alantolactone, a Natural Product Inducer of ROS
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.35265
– volume: 23
  start-page: 1102
  year: 2014
  ident: ref_36
  article-title: Dietary Flavonoid Intake and Thyroid Cancer Risk in the NIH-AARP Diet and Health Study
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-13-1150
– volume: 99
  start-page: 39
  year: 2011
  ident: ref_2
  article-title: The Epidemiology of Thyroid Disease
  publication-title: Br. Med. Bull.
  doi: 10.1093/bmb/ldr030
– volume: 114
  start-page: 393
  year: 2004
  ident: ref_5
  article-title: Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer
  publication-title: Laryngoscope
  doi: 10.1097/00005537-200403000-00001
– volume: 16
  start-page: 79
  year: 2017
  ident: ref_29
  article-title: ROS Signaling under Metabolic Stress: Cross-Talk between AMPK and AKT Pathway
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-017-0648-1
– volume: 37
  start-page: 146
  year: 2013
  ident: ref_8
  article-title: Piperlongumine Inhibits Proliferation and Survival of Burkitt Lymphoma In Vitro
  publication-title: Leuk. Res.
  doi: 10.1016/j.leukres.2012.11.009
– volume: 22
  start-page: 1473
  year: 2017
  ident: ref_16
  article-title: Piperlongumine Induces G2/M Phase Arrest and Apoptosis in Cholangiocarcinoma Cells through the ROS-JNK-ERK Signaling Pathway
  publication-title: Apoptosis
  doi: 10.1007/s10495-017-1422-y
– volume: 22
  start-page: 1894
  year: 2018
  ident: ref_53
  article-title: Honokiol Inhibits In Vitro and In Vivo Growth of Oral Squamous Cell Carcinoma through Induction of Apoptosis, Cell Cycle Arrest and Autophagy
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/jcmm.13474
– volume: 94
  start-page: 907
  year: 2018
  ident: ref_22
  article-title: Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells
  publication-title: Mol. Pharmacol.
  doi: 10.1124/mol.117.111450
– volume: 48
  start-page: 453
  year: 2013
  ident: ref_7
  article-title: Overview of the Therapeutic Potential of Piplartine (Piperlongumine)
  publication-title: Eur. J. Pharm. Sci.
  doi: 10.1016/j.ejps.2012.12.003
– volume: 16
  start-page: 6153
  year: 2015
  ident: ref_34
  article-title: New Therapies for Dedifferentiated Papillary Thyroid Cancer
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms16036153
– volume: 38
  start-page: 327
  year: 2015
  ident: ref_14
  article-title: Heme Oxygenase-1 Determines the Differential Response of Breast Cancer and Normal Cells to Piperlongumine
  publication-title: Mol. Cells
  doi: 10.14348/molcells.2015.2235
– ident: ref_50
  doi: 10.3390/ijms19010312
– volume: 37
  start-page: 10793
  year: 2016
  ident: ref_19
  article-title: Piperlongumine Induces Gastric Cancer Cell Apoptosis and G2/M cell Cycle Arrest both In Vitro and In Vivo
  publication-title: Tumour Biol.
  doi: 10.1007/s13277-016-4792-9
– volume: 103
  start-page: 1330
  year: 2005
  ident: ref_3
  article-title: Anaplastic Thyroid Carcinoma. Treatment Outcome and Prognostic Factors
  publication-title: Cancer
  doi: 10.1002/cncr.20936
– volume: 28
  start-page: 362
  year: 2015
  ident: ref_37
  article-title: Piperlongumine Induces Apoptosis and Autophagy in Human Lung Cancer Cells through Inhibition of PI3K/Akt/mTOR Pathway
  publication-title: Int. J. Immunopathol. Pharmacol.
  doi: 10.1177/0394632015598849
– volume: 39
  start-page: 801
  year: 2006
  ident: ref_25
  article-title: In Vivo Growth-inhibition of Sarcoma 180 by Piplartine and Piperine, Two Alkaloid Amides from Piper
  publication-title: Braz. J. Med. Biol. Res.
  doi: 10.1590/S0100-879X2006000600014
– volume: 48
  start-page: 269
  year: 2019
  ident: ref_48
  article-title: Diagnosis and Management of Anaplastic Thyroid Cancer
  publication-title: Endocrinol. Metab. Clin. North. Am.
  doi: 10.1016/j.ecl.2018.10.010
– volume: 494
  start-page: 165
  year: 2017
  ident: ref_21
  article-title: Piperlongumine Suppresses Bladder Cancer Invasion via Inhibiting Epithelial Mesenchymal Transition and F-actin Reorganization
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2017.10.061
– volume: 300
  start-page: 40
  year: 2019
  ident: ref_40
  article-title: Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 Prostate Cancer Cells-The Involvement of Carbonyl Reductase 1 Inhibition
  publication-title: Chem. Biol. Interact.
  doi: 10.1016/j.cbi.2019.01.003
– volume: 109
  start-page: 1462
  year: 2019
  ident: ref_20
  article-title: Piperlongumine, a Piper Alkaloid Targets Ras/PI3K/Akt/mTOR Signaling Axis to Inhibit Tumor Cell Growth and Proliferation in DMH/DSS Induced Experimental Colon Cancer
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.10.182
– volume: 33
  start-page: 305
  year: 2018
  ident: ref_33
  article-title: Spectroscopic Investigation of the Anticancer Alkaloid Piperlongumine Binding to Human Serum Albumin from the Viewpoint of Drug Delivery
  publication-title: Luminescence
  doi: 10.1002/bio.3414
– volume: 63
  start-page: 6784
  year: 2003
  ident: ref_31
  article-title: Thyroid Cancer Resistance to Chemotherapeutic Drugs Via Autocrine Production of Interleukin-4 and Interleukin-10
  publication-title: Cancer Res.
– volume: 437
  start-page: 87
  year: 2013
  ident: ref_10
  article-title: Piperlongumine Selectively Kills Glioblastoma Multiforme Cells via Reactive Oxygen Species Accumulation Dependent JNK and p38 Activation
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2013.06.042
– volume: 45
  start-page: 1329
  year: 2014
  ident: ref_27
  article-title: Redox-directed Cancer Therapeutics: Taurolidine and Piperlongumine as Broadly Effective Antineoplastic Agents (Review)
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2014.2566
– volume: 1443
  start-page: 3
  year: 2019
  ident: ref_35
  article-title: Effects of Phytochemicals on Thyroid Function and Their Possible Role in Thyroid Disease
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.13980
– volume: 2011
  start-page: 792639
  year: 2011
  ident: ref_28
  article-title: Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?
  publication-title: J. Signal. Transduct.
  doi: 10.1155/2011/792639
– volume: 5
  start-page: 9227
  year: 2014
  ident: ref_12
  article-title: Piperlongumine Selectively Kills Cancer Cells and Increases Cisplatin Antitumor Activity in Head and Neck Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2402
– volume: 66
  start-page: 642
  year: 2012
  ident: ref_49
  article-title: Autophagy Induction of Reversine on Human Follicular Thyroid Cancer Cells
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2012.08.001
– volume: 10
  start-page: 709
  year: 2015
  ident: ref_24
  article-title: JNK Signaling Pathway is Involved in Piperlongumine-mediated Apoptosis in Human Colorectal Cancer HCT116 Cells
  publication-title: Onco.l Lett.
  doi: 10.3892/ol.2015.3371
– volume: 156
  start-page: 13
  year: 2018
  ident: ref_38
  article-title: Piperlongumine (Piplartine) as a Lead Compound for Anticancer Agents-Synthesis and Properties of Analogues: A Mini-review
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.06.057
– volume: 29
  start-page: 1990
  year: 2012
  ident: ref_4
  article-title: Reversine, a 2,6-Disubstituted Purine, as an Anti-cancer Agent in Differentiated and Undifferentiated Thyroid Cancer Cells
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-012-0727-3
– volume: 70
  start-page: 502
  year: 2018
  ident: ref_9
  article-title: Piperlongumine Induces Apoptosis in Human Melanoma Cells Via Reactive Oxygen Species Mediated Mitochondria Disruption
  publication-title: Nutr. Cancer
  doi: 10.1080/01635581.2018.1445769
– volume: 1795
  start-page: 92
  year: 2009
  ident: ref_47
  article-title: Human Cancer Cell Lines: Experimental Models for Cancer Cells in Situ? For Cancer Stem Cells?
  publication-title: Biochim. Biophys. Acta.
SSID ssj0000331767
Score 2.402512
Snippet Thyroid cancer (TC) is the most common endocrine malignancy, and its global incidence has steadily increased over the past 15 years. TC is broadly divided into...
Simple SummaryThere is no effective treatment currently available for patients with anaplastic, recurrent papillary, or follicular thyroid cancers. Reactive...
SourceID pubmedcentral
proquest
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 4266
SubjectTerms AKT protein
Antitumor activity
Apoptosis
Caspase
Cell cycle
Cell growth
Cell proliferation
Cell viability
Malignancy
Mitochondria
Patients
Piper longum
Reactive oxygen species
Signal transduction
Thyroid cancer
TOR protein
Tumorigenesis
Tumors
Xenografts
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiKdYKMhIHDg0bJqXkxNaVq0qpJaotKi3yHYm3YjFDkkWtP-JH8lM1rvtIsEpiu1kLM94Hn7Mx9hbCaKSpVIehsjCIzgLT4mq8gjCLvbRvgSC7jufniUnl9Gnq_jKLbh17ljlRicOirq0mtbIJ4S2lgQUXXxofniEGkW7qw5C4y7bQxWcpiO29_HoLD_frrL4IdrHRKxz-oQY3080DWbbHWI5Gaddc3TjY-6ekLxlco4fsgfOV-TTNXMfsTtgHrN7p243_An7ndcNtAtrrpffseCAS55b9IF7PjW0RE1d4Pl81d--ZXXACa0DtQOfwWLBZyv8NZIgiA4uTcmnjW1629UdtuNf6761Q_Hw8tNyh-uDT-Dnn79Mpt96nqMX-UuueG34sCfAL-ar1tYln627QIS6p-zy-OhiduI59AVPh1nae6DQdUkUSIljCBDr4LDUWaRjgTGlDMpYxb6WVQZ-JBNfVxiXhEBnLlI_FEEE4TM2MtbAc8a1gixGidBQhRHEQqE4-BDqRAqdqRLG7P2GCYV2qckJIWNRYIhCXCv-4tqYvdt-0Kyzcvy76f6Gq4Wbnl1xI0xj9mZbjROLdkukAbsc2qD3SxHUmIkdadiSpNTcuzWmng8pulOM6tBXffF_4i_Z_YCOyPiorKJ9NurbJbxCH6dXr50g_wGNWwMw
  priority: 102
  providerName: ProQuest
Title Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells
URI https://www.proquest.com/docview/2570621917
https://www.proquest.com/docview/2571920049
https://pubmed.ncbi.nlm.nih.gov/PMC8428232
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFLXYJiFeEJ-ibFRG4oGHZUvz5eYBoVJtTEgd0VhR3yLbuVkjgtMlKZD_xI_k3jTtVjQknqLETmz53vieEzv3MPZGgkhlopSFFFlYJGdhKZGmFknY-TbGF0fQ_86T8-Bs6n2a-bMbOaBuAKs7qR3pSU3L_OjXdfMeX_h3xDiRsh9rGp-yGmAopHizw_YwLAmSM5h0WL-dll0sbxVlHVs4VhCE3irVz13P2I5SN9Bze-PkrUh0-og97CAkH61s_pjdA_OE3Z90i-RP2e8oW0CZF-Zq-R0vHHLJowKhcc1Hhr5cUxd4NG_q2z9fHXIS8cBJg48hz_m4wUdjE6TcwaVJ-GhRLOqiyiqsx79mdVm0l9uTHwXv5H7wCPzi85fj0beaRwguf8qGZ4a3SwX8ct6URZbw8aoL1FD1jE1PTy7HZ1YnymBpNxzWFihENIECKXE8AXztDBIdetoXSDWlk_jKt7VMQ7A9Gdg6RbriAm3FGNqucDxwn7NdUxh4wbhWEProKBpS1wNfKPQSG1wdSKFDlUCPHa2NEOsuYzkJZ-QxMheyWvyX1Xrs7eaGxSpZx7-rHqytGq-dLiZFv8AhBttjrzfF-L7RIoo0UCzbOgiKiVj1mNjyhk2TlLF7u8Rk8zZz9xDJHkLYl__fz332wKFdNDbOZ94B263LJbxCGFSrPtv7cHIeXfTZzsfZoN86-x8NGg39
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviE_RMcBIIPGw0DRO4uYBoVI2dWwt1ejQ3oLjXNaIkoQkZer_hPgbuUvSbkWCtz1FsR2fpbvch8--H2MvFchIhUFgYIgsDYKzMAIZRQZB2Dkm2hdL0n3n0dgdntofz5yzLfZ7dReGjlWudGKlqMNU0x55h9DWXIuii3fZD4NQoyi7uoLQqMXiCJYXGLIVbw8_IH9fWdbB_nQwNBpUAUMLr1caEKBJdgNQSogugKOtbqg9WzsSYyVlhU7gmFpFHpi2ck0dob8tgM4S9EwhLRsEznuDbdvCNa0W236_P56crHd1TJxTurKuISSEZ3Y0MS8vuthOxnDT_F36tJsnMq-YuIO77E7jm_J-LUz32BYk99nNUZN9f8B-TeIM8nmanC--Y8MeV3ySos9d8n5CW-K0BD6ZLcurt7r2OKGDoDbiA5jP-WCJUyMJggThKgl5P0uzMi3iAsfxL3GZp1Vz9fIz5Q2OED6Bn3z63Ol_K_kEvdYLteRxwqscBJ_Olnkah3xQL4EIFQ_Z6bXw5RFrJWkCjxnXAXgOSqCGSNjgyADFzwShXSW1F4TQZm9WTPB1UwqdEDnmPoZExDX_L6612ev1B1ldBeTfQ3dXXPUbdVD4l8LbZi_W3fgjU3ZGJZAuqjHobVPE1mZyQxrWJKkU-GZPEs-qkuA9jCLRN975P_Hn7NZwOjr2jw_HR0_YbYuO55ioKO1d1irzBTxF_6oMnjVCzdnX6_6P_gC8Oz-_
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVKq4IJ4itMAigcShJo5fGx8QCmmjltJglRb1ZtbrMbEabGM7VP5P_AJ-HTN-pA0S3HqyvF7vrDSz89idnY-xlxJEJMMg0DBEFhrBWWiBiCKNIOxsHe2LIei-8_HMOTizPpzb5xvsd3cXhtIqO51YK-owVbRHPiC0Nceg6GIQtWkR3t70XfZDIwQpOmnt4DQaETmC6hLDt-Lt4R7y-pVhTPdPJwdaizCgKdMdlRoEaJ6dAKQ0zSGArYxhqFxL2QLjJmmEdmDrSkYu6JZ0dBWh720C5RWMdFMYFpg47i22KSgq6rHN9_sz72S1w6PjmMIRTT0h03T1gSJG5sUQ28kwrpvCK_92PTvzmrmb3mV3Wj-VjxvBusc2ILnPto7bk_gH7JcXZ5Av0uTb8js27HLJvRT975KPE9oepylwb16V12947XJCCkHNxCewWPBJhUMjCYIH4TIJ-ThLszIt4gL78S9xmad1c_3yM-UtphA-gZ98-jwYX5TcQw_2UlY8Tnh9HsFP51WexiGfNFMgQsVDdnYjfHnEekmawGPGVQCujdKoIDItsEWAoqiDqRwplBuE0GdvOib4qi2LTugcCx_DI-Ka_xfX-uz16oesqQjy7647HVf9VjUU_pUg99mL1Wdc1HRSIxNIl3Uf9LwpeuszsSYNK5JUFnz9SxLP6_LgI4wo0U9-8n_iz9kWrh__4-HsaJvdNihTR0edae2wXpkv4Sm6WmXwrJVpzr7e9DL6AyV_Q_Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Piperlongumine%2C+a+Potent+Anticancer+Phytotherapeutic%2C+Induces+Cell+Cycle+Arrest+and+Apoptosis+In+Vitro+and+In+Vivo+through+the+ROS%2FAkt+Pathway+in+Human+Thyroid+Cancer+Cells&rft.jtitle=Cancers&rft.au=Kung%2C+Fang-Ping&rft.au=Lim%2C+Yun-Ping&rft.au=Chao%2C+Wen-Ying&rft.au=Zhang%2C+Yi-Sheng&rft.date=2021-08-24&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=13&rft.issue=17&rft.spage=4266&rft_id=info:doi/10.3390%2Fcancers13174266&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_cancers13174266
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon